A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

NCT06617325 · clinicaltrials.gov ↗
PHASE3
Phase
RECRUITING
Status
450
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

UCB Biopharma SRL